Forte Biosciences is a clinical-stage biopharmaceutical company developing therapies for autoimmune and related immune-mediated conditions. Its pipeline has centered on investigational biologic candidates rather than marketed products, so near-term economics depend on R&D progress. The company targets specialist physician and patient populations in areas of high unmet medical need.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 0 | — | -15.7 | — |
| Q2 2025 | 0 | — | -11.3 | — |
| Q3 2025 | 0 | — | -17.7 | — |
| Q4 2025 | 0 | — | -24.8 | — |
| Q1 2026 | 0 | — | -22.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Capital Southwest Corporation (CSWC), QCR Holdings, Inc. (QCRH), Distribution Solutions Group, Inc. (DSGR), Uranium Royalty Corp. (UROY), Omnicell, Inc. (OMCL), ICF International, Inc. (ICFI)